This medical services company has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
BioTelemetry currently has a Zacks Rank #1 (Strong But) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same industry include ICON plc (ICLR), Quintiles Transnational Holdings Inc. (Q) and Cancer Genetics, Inc. (CGIX). While ICON and Quintiles Transnational Holdings hold a Zacks Rank #1 (Strong Buy), Cancer Genetics carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment